Zhejiang Jingxin Pharmaceutical Co Ltd

Zhejiang Jingxin Pharmaceutical Co Ltd maintains a strong liquidity position, with a current ratio of 1.73, indicating the company can cover its short-term liabilities with its short-term assets. The company's liquidity_fpt score is positive, supported by a free cash flow of 554.83 million CNY and a net cash position that is negative after subtracting total debt. The company's debt-to-equity ratio is 0.05, suggesting a conservative capital structure with minimal leverage. In terms of profitability, the company's return on equity (ROE) of 12.99% and return on assets (ROA) of 9.33% are strong, outperforming the typical benchmarks for the pharmaceutical industry. The net income of 757.98 million CNY and operating income of 862.60 million CNY reflect a healthy margin structure, with a gross profit of 2.01 billion CNY supporting these figures. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond the domestic Chinese market. This concentration may expose the company to regional economic and regulatory risks, though the company's strong domestic presence and product portfolio may mitigate some of these concerns. Looking ahead, the company is expected to maintain a stable growth trajectory, with analysts forecasting a mean EPS of 1.06 CNY for the current fiscal year, compared to the actual EPS of 0.92 CNY. The company's capital expenditure of -202.85 million CNY suggests a reduction in investment, which may indicate a focus on cost optimization or a shift in strategic priorities. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The risk assessment indicates that the company has a manageable debt load and a strong equity base, with a total equity of 5.83 billion CNY. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. Recent events and filings show a positive analyst sentiment, with a mean recommendation of 1.40, indicating a strong buy to buy rating. The company has received three strong-buy ratings and two buy ratings, with no hold, sell, or strong-sell ratings. This suggests that the market views the company favorably, with expectations of continued performance and growth.